VERTEX PHARMACEUTICALS INCORPORATED

HCR · Health Issues

Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.

Literal federal measure citations: H.R. 6423, S. 864

MMM · Medicare/Medicaid

Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals.

Literal federal measure citations: H.R. 1227, S. 475

TAX · Taxation/Internal Revenue Code

Corporate tax reform; H.R. 1414 - Cameron's Law, Preservation of Orphan Drug Tax Credit; Restoration of Sec 174 R&D Expense Deductibility.

Literal federal measure citations: H.R. 1414

BUD · Budget/Appropriations

Education about non-opioid pain therapies and patient access to non-opioid medicines; Education on alternative funding programs; Education on the Million Veteran Program at the VA.

TRD · Trade (domestic/foreign)

Intellectual property reforms to address unfair trade practices in Argentina and Russia.

PHA · Pharmacy

Issues related to the National Defense Authorization Act - access to non-opioids for service members and their families; Issues related to the NDAA S.Amdt.3841 BIOSECURE Act.

VET · Veterans

Issues related to veteran's access to non-opioid alternatives and implementation of report language in the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (PL 119-37).